// App-Quantinova.ai

: Post‐marketing surveillance study of the safety of dexamethasone intravitreal implant (DEX) in patients with retinal vein occlusion (RVO) or noninfectious posterior segment uveitis (NIPSU)

Researchers

Presenter

  • N.M. Gajate

Principal Investigators

  • A. Tufail

  • S. Lightman

  • A. Kamal

  • U. Pleyer

  • C. Dot

  • X.Y. Li

  • J. Jiao

  • J. Lou

  • Y. Hashad

Medical Centers

  • Servicio de Oftalmología, Hospital Universitario de Burgos, Burgos, Spain

  • Ophthalmology, Moorfields Eye Hospital, London, UK

  • Ophthalmology, Aintree University Hospital, Liverpool, UK

  • Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Ophthalmology, Ophtalmologie ‐ Hôpital Desgenettes, Lyon, France

  • Clinical Development, Allergan plc, Irvine, USA

  • Biostatistics, Allergan plc, Irvine, USA

Locations

  • Spain

  • United Kingdom

  • Germany

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Ophthalmology (OP)

Disease

  • Retinal vein occlusion

  • Uveitis

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved